Foamix’s FMX103 meets efficacy endpoints in phase 2 trial for papulopustular rosacea
A phase 2 clinical trial evaluating Foamix Pharmaceuticals' FMX103 to treat moderate-to-severe papulopustular rosacea (PR) demonstrated statistically significant improvement compared with vehicle in the main efficacy endpoints.
Click on this link for more information.
